• Alvotech announced that the U.S. Food and Drug Administration has closed its May 2026 inspection of the company’s Reykjavik, Iceland manufacturing facility with a Voluntary Action Indicated classification, confirming that the actions taken have addressed the FDA’s observations and allowing the company to continue advancing multiple Biologics License Applications for its biosimilar candidates.
• This outcome, together with recent resubmissions and acceptance of BLAs for biosimilars to Simponi, Eylea and Entyvio, highlights how regulatory progress at a key manufacturing site underpins Alvotech’s efforts to broaden access to high-quality, lower-cost biologic medicines worldwide.
• With the FDA inspection now closed and the Reykjavik facility classified as Voluntary Action Indicated, we’ll examine how this regulatory milestone shapes Alvotech’s investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Alvotech Investment Narrative Recap

To own Alvotech, you need to believe in its ability to turn a focused biosimilar pipeline and global partnerships into durable, higher quality revenues while managing debt and pricing pressure. The FDA’s Voluntary Action Indicated outcome for the Reykjavik site reduces near term regulatory overhang, which matters for approval timing, but the biggest swing factor and risk still centers on how quickly key U.S. biosimilar launches convert into meaningful, less lumpy cash flows.

The most relevant recent update is the FDA’s acceptance of Alvotech’s BLA for AVT16, its proposed biosimilar to Entyvio, alongside resubmissions for AVT05 and AVT06. These applications rely directly on confidence in the Reykjavik facility, so closing the inspection with a VAI classification supports the near term regulatory catalyst path, even though actual approval decisions, pricing outcomes and uptake remain the critical unknowns for how much value these assets can ultimately contribute.

Yet, while the FDA inspection outcome is encouraging, investors should still be aware that Alvotech’s heavy reliance on lumpy milestone revenues tied to future approvals could...

Alvotech's narrative projects $1.0 billion revenue and $242.3 million earnings by 2029.

Uncover how Alvotech's forecasts yield a $5.75 fair value, a 51% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming about US$983 million of revenue and US$83 million of earnings by 2029, and the new FDA outcome may either soften or reinforce that more pessimistic view depending on how you weigh the remaining approval timing and partner execution risks.

Explore 5 other fair value estimates on Alvotech - why the stock might be worth just $4.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.